4.8 Article

Spherical nucleic acids as an infectious disease vaccine platform

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2119093119

关键词

antiviral vaccines; spherical nucleic acids; rational vaccinology; infectious disease

资金

  1. Northwestern University
  2. Air Force Office of Scientific Research Award [FA9550-17-10348]
  3. Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital
  4. National Cancer Institute of NIH [R01CA208783, P50CA221747]
  5. Northwestern University's Cancer Nanotechnology Training Program - National Cancer Institute of NIH [T32CA186897]
  6. Edward Bachrach
  7. Dr. John N. Nicholson Fellowship
  8. University of Chicago Biological Sciences Division
  9. NCI Cancer Center Support Grant (CCSG) [P30 CA060553]
  10. NIH Office of Director [S10OD025194]
  11. Soft and Hybrid Nanotechnology Experimental Resource [NSF ECCS-2025633]
  12. State of Illinois
  13. International Institute for Nanotechnology
  14. [P41 GM108569]

向作者/读者索取更多资源

This study explores how the presentation of vaccine components in spherical nucleic acids (SNAs) can induce and maximize antiviral response. The SNA vaccine, encapsulating the receptor-binding domain (RBD) subunit and decorated with Toll-like receptor 9 agonist oligonucleotides, shows promising results in inducing immune responses in human cells and mice, outperforming traditional vaccines.
Despite recent efforts demonstrating that organization and presentation of vaccine components are just as important as composition in dictating vaccine efficacy, antiviral vaccines have long focused solely on the identification of the immunological target. Herein, we describe a study aimed at exploring how vaccine component presentation in the context of spherical nucleic acids (SNAs) can be used to elicit and maximize an antiviral response. Using COVID-19 as a topical example of an infectious disease with an urgent need for rapid vaccine development, we designed an antiviral SNA vaccine, encapsulating the receptor-binding domain (RBD) subunit into a liposome and decorating the core with a dense shell of CpG motif toll-like receptor 9 agonist oligonucleotides. This vaccine induces memory B cell formation in human cells, and in vivo administration into mice generates robust binding and neutralizing antibody titers. Moreover, the SNA vaccine outperforms multiple simple mixtures incorporating clinically employed adjuvants. Through modular changes to SNA structure, we uncover key relationships and proteomic insights between adjuvant and antigen ratios, concepts potentially translatable across vaccine platforms and disease models. Importantly, when humanized ACE2 transgenic mice were challenged in vivo against a lethal live virus, only mice that received the SNA vaccine had a 100% survival rate and lungs that were clear of virus by plaque analysis. This work underscores the potential for SNAs to be implemented as an easily adaptable and generalizable platform to fight infectious disease and demonstrates the importance of structure and presentation in the design of next-generation antiviral vaccines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据